Regulus Therapeutics Inc (RGLS) — Cash Flow-to-Debt Ratio
Regulus Therapeutics Inc (RGLS) has a Cash Flow-to-Debt Ratio of -1.83x as of March 2025, meaning its operating cash flow of $-10.61 Million could theoretically repay -2% of its total liabilities ($5.80 Million) in one year. See RGLS cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Regulus Therapeutics Inc Cash Flow-to-Debt Ratio (2010–2024)
Historical debt coverage capacity for Regulus Therapeutics Inc across 15 annual periods. Also explore net asset growth rate of Regulus Therapeutics Inc to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Regulus Therapeutics Inc (2010–2024)
Year-by-year debt coverage analysis for Regulus Therapeutics Inc. For market capitalisation and broader financial context, see Regulus Therapeutics Inc stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -5.36x | $-41.67 Million | $7.77 Million | ▼ -91.5% |
| 2023 | -2.80x | $-26.77 Million | $9.56 Million | ▼ -47.2% |
| 2022 | -1.90x | $-25.53 Million | $13.43 Million | ▼ -6.4% |
| 2021 | -1.79x | $-24.13 Million | $13.50 Million | ▼ -65.1% |
| 2020 | -1.08x | $-12.54 Million | $11.58 Million | ▼ -20.5% |
| 2019 | -0.90x | $-19.82 Million | $22.07 Million | ▲ +29.9% |
| 2018 | -1.28x | $-43.27 Million | $33.78 Million | ▲ +7.2% |
| 2017 | -1.38x | $-58.77 Million | $42.59 Million | ▼ -8.2% |
| 2016 | -1.28x | $-56.88 Million | $44.59 Million | ▲ +56.5% |
| 2015 | -2.93x | $-49.86 Million | $17.00 Million | ▼ -192.9% |
| 2014 | -1.00x | $-39.51 Million | $39.47 Million | ▼ -4.6% |
| 2013 | -0.96x | $-28.33 Million | $29.61 Million | ▼ -354.5% |
| 2012 | -0.21x | $-8.72 Million | $41.42 Million | ▼ -17.9% |
| 2011 | -0.18x | $-15.06 Million | $84.38 Million | ▼ -175.0% |
| 2010 | 0.24x | $12.31 Million | $51.71 Million | — |